What Can Cause a Positive Drug Test for Buprenorphine?

A positive drug test for buprenorphine most commonly reflects actual exposure to the drug, whether through a legitimate prescription, illicit use, or, in rarer cases, interference from another medication. Buprenorphine is a partial opioid used to treat opioid use disorder and chronic pain, and it requires its own targeted test because standard opiate immunoassays do not reliably pick it up. That distinction matters because the reasons for a false positive on a buprenorphine-specific test are different from those that trip up a general opiate screen, and at least one common psychiatric medication has been shown to cause interference even on advanced confirmatory testing.

Prescribed Use Is the Most Common Explanation

The single most frequent reason someone tests positive for buprenorphine is that they are taking it as prescribed. Buprenorphine is widely used in office-based opioid treatment programs under brand names like Suboxone, Subutex, Zubsolv, and Sublocade. Patients in these programs are routinely tested not to catch them using buprenorphine but to confirm they are actually taking it. In one study of patients prescribed buprenorphine, nearly all urine specimens from those taking their medication tested positive, with detection rates around 97 percent in urine samples.¹ When doctors order a buprenorphine-specific panel for a patient in treatment, they expect a positive result. A negative result is actually the red flag in that context, suggesting the patient may not be taking the medication.

If you are prescribed buprenorphine and tested at a workplace, a pain clinic, or an emergency department, the positive result simply reflects your medication. Having documentation of the prescription, or giving the testing entity permission to contact your prescribing physician, is usually enough to resolve any concern. The test itself cannot tell whether the buprenorphine came from a prescription or from illicit use. That determination is made through medical records and clinical context.

Quetiapine and the Medication That Fools Even Advanced Tests

Among the more surprising causes of a buprenorphine-positive result is quetiapine, an antipsychotic sold under the brand name Seroquel. Quetiapine is prescribed for schizophrenia, bipolar disorder, and sometimes insomnia or anxiety. Its metabolites can structurally mimic norbuprenorphine, which is the main metabolite that labs look for when confirming buprenorphine use. What makes this interference particularly troublesome is that it does not just fool the initial screening test. Researchers have documented that quetiapine metabolites can produce false-positive results even on liquid chromatography-tandem mass spectrometry, the gold-standard confirmation method that is supposed to be the final word on whether buprenorphine is truly present.²

This happens because certain quetiapine metabolites share molecular weight and fragmentation patterns with norbuprenorphine. The confirmation instrument monitors specific molecular transitions to identify the drug, and if the interfering substance breaks apart in a similar enough way, the test registers a match. That study found the interference occurred at the transition points the lab used to identify norbuprenorphine, meaning a patient taking only quetiapine could produce a result that looked indistinguishable from genuine buprenorphine use on both the screening and confirmatory tests.²

This is not a theoretical concern. Quetiapine is one of the most commonly prescribed antipsychotics, and many patients taking it are in treatment settings where buprenorphine testing is routine. If you take quetiapine and receive an unexpected positive buprenorphine result, this interference is a documented and well-characterized explanation worth raising with your provider or the medical review officer.

How Immunoassay Cross-Reactivity Works in Drug Testing

Most drug tests begin with an immunoassay, a relatively quick and inexpensive screening method. Immunoassays use antibodies designed to bind to a target drug or its metabolites. The problem is that these antibodies are not perfectly selective. If another substance has a shape or charge profile similar enough to the target, the antibody may bind to it and register a positive. This is called cross-reactivity, and it is a well-known limitation of initial drug screens across all drug classes.

For opioid testing more broadly, a variety of common medications have been documented to trigger false positives on immunoassay screens. Medications including verapamil (a blood pressure drug), diphenhydramine (Benadryl), and doxylamine (an antihistamine found in sleep aids) have all been reported to cause false-positive results on certain opioid-class immunoassays.³ While those specific interferences have been documented on methadone-specific immunoassays rather than buprenorphine-specific ones, the underlying principle is the same: immunoassays trade some specificity for speed and cost savings, and unexpected positives happen.

Buprenorphine-specific immunoassays are targeted tests, distinct from the broad opiate panels that look for morphine, codeine, and related drugs. Standard opiate screens will generally not detect buprenorphine at all because its molecular structure is different enough to evade those antibodies. A lab has to specifically test for buprenorphine. This means that for a false positive to occur on a buprenorphine-specific screen, the interfering substance has to be structurally similar to buprenorphine or norbuprenorphine in particular, which narrows the field of potential culprits compared to broader opiate screens.

When Confirmatory Testing Should Settle It

The standard practice when a screening immunoassay returns positive is to run a confirmatory test using liquid chromatography-tandem mass spectrometry. This method physically separates the molecules in a sample and identifies them by their unique molecular fragmentation patterns, achieving far higher specificity than an immunoassay.⁴ In most drug testing scenarios, a positive screen followed by a negative confirmation is reported as negative. The confirmatory test is the tiebreaker.

For buprenorphine, confirmatory testing looks for both the parent drug and norbuprenorphine. A genuine positive typically shows both compounds present, often in a predictable ratio. In patients taking buprenorphine as prescribed, urine samples consistently show norbuprenorphine alongside the parent drug, with the ratio of buprenorphine to norbuprenorphine staying below a certain threshold that reflects normal metabolism.⁵ That ratio can actually serve as a clue about whether someone is genuinely taking the drug or whether the result is an artifact.

The quetiapine interference described earlier is unusual precisely because it beats the confirmatory test too. Most false positives are caught and corrected at the confirmation stage. When an interfering substance can mimic the molecular signature of norbuprenorphine on mass spectrometry, the safeguard fails. Labs aware of this issue can adjust their confirmation methods by using different molecular transition channels or by adding quetiapine metabolites to their monitoring protocol, but not all labs have made these updates. If you take quetiapine and face a confirmed positive for buprenorphine, requesting that the lab specifically evaluate for quetiapine interference is a reasonable step.

Detection Windows and Why the Testing Matrix Matters

How long buprenorphine stays detectable depends on the specimen type. Urine is the most commonly used matrix and also the most sensitive for detecting buprenorphine and its metabolites. In a direct comparison, urine detected buprenorphine use in 97 percent of patients known to be taking the drug, while oral fluid (saliva testing) caught only about 78 percent.¹ Oral fluid has a shorter detection window because buprenorphine concentrations in saliva drop faster than in urine.

In urine, buprenorphine is generally detectable for several days after the last dose, though the exact window varies with dose, duration of use, individual metabolism, and kidney function. Chronic users who take buprenorphine daily for months accumulate the drug in tissue, which can extend the detection window. Someone who takes a single sublingual dose may test positive in urine for roughly three to six days, while a long-term daily user could test positive for a week or more after stopping. Hair and blood testing are less commonly used but do exist. Blood tests have the shortest window, typically detecting buprenorphine for only about 24 to 48 hours. Hair testing can theoretically detect use over months, though it is rarely employed for buprenorphine outside of forensic or research contexts.

The practical upshot is that a positive urine test for buprenorphine means exposure occurred within the past several days. It does not pinpoint when the drug was taken or in what amount. Quantitative levels in urine are influenced by hydration, kidney function, and time since the last dose, so a higher concentration does not automatically mean a higher dose was taken.

Sample Adulteration and Spiking

An unusual but documented cause of a positive buprenorphine result is deliberate tampering with the urine sample. In treatment settings where patients are expected to test positive for buprenorphine to prove compliance, individuals who have diverted (sold) their medication sometimes crush a buprenorphine tablet and add it directly to the urine cup to simulate normal use.⁶ This produces a sample that tests positive for buprenorphine but may have telltale signs that distinguish it from genuine metabolized drug.

One of the clearest giveaways is an abnormal buprenorphine-to-norbuprenorphine ratio. When you swallow or dissolve buprenorphine under your tongue, your liver converts a substantial portion of it into norbuprenorphine. A legitimately positive urine sample shows both compounds. A spiked sample, on the other hand, tends to show a very high concentration of the parent drug with little or no norbuprenorphine, because the drug was never metabolized. Labs and clinicians who monitor quantitative levels and metabolite ratios can often distinguish genuine adherence from spiking.⁵ In a study of patients taking prescribed buprenorphine, all urine samples showed both buprenorphine and norbuprenorphine in expected ratios, confirming that the metabolite pattern is consistent and predictable when the drug is genuinely being taken.

Illicit Use and Diversion

Outside of treatment programs, buprenorphine is sometimes used illicitly. It circulates on the black market, often in the form of diverted Suboxone strips or generic sublingual tablets. Someone who uses buprenorphine obtained from another person will test positive just as someone with a prescription would, and there is no way for the test itself to distinguish between the two. The same is true for someone who is exposed to buprenorphine unknowingly, though this is uncommon. Unlike fentanyl, which has been found as a contaminant in various street drugs, buprenorphine is not a typical adulterant in the illicit drug supply. If buprenorphine shows up on a drug test, incidental or accidental exposure is a much less likely explanation than intentional use or a testing error.

That said, buprenorphine has occasionally been found in counterfeit pills or mixed into heroin in some markets. Someone who uses street drugs and tests positive for buprenorphine without knowingly taking it should consider the possibility that whatever they consumed was not what they thought it was.

What to Do If You Get an Unexpected Result

If you test positive for buprenorphine and you have not taken it, the first step is to ask whether the result was confirmed. An unconfirmed immunoassay result is preliminary and should not be treated as definitive. In workplace testing governed by federal rules, a Medical Review Officer is required to review positive results and contact the donor before reporting, which gives you the chance to disclose any prescriptions or request additional analysis. In clinical settings, the process is less standardized, and a positive screening result may be acted on without confirmation unless you advocate for further testing.

If the result was confirmed by mass spectrometry and you take quetiapine, inform the reviewing physician and request that the lab evaluate for quetiapine metabolite interference specifically. Not all confirmation methods are equally susceptible to this issue, and a lab that is aware of the problem can adjust its protocol. If you do not take quetiapine or any other medication that could explain the result, requesting a retest on a fresh sample or on a split specimen (if one was collected) is reasonable.

Keep in mind that drug testing in clinical treatment programs and workplace settings operates under different rules. Treatment programs often use point-of-care cups that provide immediate results without automatic laboratory confirmation. These cup tests are particularly susceptible to cross-reactivity. If a point-of-care test is the basis for a clinical decision you disagree with, asking for a laboratory-confirmed retest is within your rights.

Why Buprenorphine Gets Its Own Test Panel

People sometimes wonder why buprenorphine is not caught on a standard opiate drug screen. The reason is molecular. Standard opiate immunoassays are designed to detect morphine and structurally similar compounds like codeine, heroin metabolites, and hydrocodone. Buprenorphine’s structure is different enough that these antibodies largely ignore it. A person taking buprenorphine can test negative on a standard five-panel or ten-panel drug test that includes “opiates” as a category, which is why labs offer a separate buprenorphine-specific assay. This is also why buprenorphine false positives are a distinct problem from the more commonly discussed false positives on general opiate screens, where poppy seeds, certain cough medicines, and other opioids can all trigger a hit. Those cross-reactivities do not carry over to buprenorphine-specific tests. The substances that interfere with buprenorphine testing are a different and smaller set, with quetiapine being the best-documented offender.

This separate-panel design also means that if you see “opiates: positive” on a test result, that does not indicate buprenorphine. And if you see “buprenorphine: positive,” that does not mean you would also test positive for opiates in the traditional sense. The two panels are independent and look for different molecules. Understanding this distinction can prevent confusion when reading multi-panel test reports, especially in clinical settings where both panels may be ordered simultaneously.